6505--Carbidopa Levodopa Immediate Release (IR) Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAC PHARMACEUTICALS (36E797)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36E79726R0008

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Department of Veterans Affairs (VA), through its National Acquisition Center (NAC) Pharmaceuticals office, has issued a solicitation for the supply of Carbidopa Levodopa Immediate Release (IR) Tablets. This procurement, identified under solicitation number 36E79726R0008, seeks to secure a reliable source of this essential pharmaceutical product, which is widely used in the treatment of Parkinson’s disease and related neurological disorders. The primary objective of this solicitation is to ensure the continued availability of high-quality Carbidopa Levodopa IR Tablets for VA healthcare facilities, thereby supporting the ongoing care and well-being of veterans nationwide. The scope of this procurement encompasses the manufacturing and delivery of Carbidopa Levodopa IR Tablets in accordance with all applicable federal regulations and pharmaceutical industry standards. Offerors are expected to demonstrate their capability to consistently supply this medication, meeting stringent quality assurance and regulatory compliance requirements. The expected deliverables include timely and reliable provision of the specified pharmaceutical product, with adherence to all labeling, packaging, and distribution protocols as outlined in the solicitation documents and any subsequent amendments. This opportunity is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), reflecting the requirement for specialized expertise in the production of pharmaceutical preparations. The associated Product Service Code (PSC) is 6505, which pertains to drugs and biologicals. The procurement is managed by the NAC Pharmaceuticals office, a federal entity within the Department of Veterans Affairs, ensuring that the contract will be administered in accordance with federal acquisition regulations and VA-specific policies. Interested contractors should note that the solicitation is currently active, with the response deadline extended as indicated in the most recent amendment. All prospective offerors are encouraged to review the amendment document for updated submission timelines and any changes to the solicitation requirements. The primary point of contact for this procurement is Ray Roldan, who can be reached via email at [email protected] for any questions or clarifications regarding the solicitation. Contractors considering this opportunity should ensure that they possess the necessary manufacturing capabilities, regulatory approvals, and distribution infrastructure to meet the VA’s requirements for Carbidopa Levodopa IR Tablets. While specific set-aside requirements or special considerations are not detailed in the provided notice, offerors are advised to consult the full solicitation and associated attachments available on SAM.gov for comprehensive instructions and compliance obligations. In summary, this procurement represents a significant opportunity for qualified pharmaceutical manufacturers to partner with the Department of Veterans Affairs in supporting the health needs of veterans through the supply of Carbidopa Levodopa Immediate Release Tablets. Interested parties should act promptly to review the solicitation documents and submit their offers by the specified deadline.